← FDA DRUG APPROVALS

FDA ANDA · ANDA201887

ENSKYCE

desogestrel and ethinyl estradiol

Sponsor: LUPIN LTD

APPLICATION
ANDA201887
TYPE
ANDA
ORIGINAL APPROVAL
2013-03-07
LATEST ACTION
2022-04-29
ROUTE
ORAL-28
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

ENSKYCEPrescription
DESOGESTREL 0.15MG, ETHINYL ESTRADIOL 0.03MG · TABLET · ORAL-28

Approval history

2022-04-29Labeling · Supplement 19 · standardAP
2019-11-15Manufacturing (CMC) · Supplement 15 · unknownAP
2019-05-23Labeling · Supplement 10 · standardAP
2019-05-23Labeling · Supplement 8 · standardAP
2019-05-23Manufacturing (CMC) · Supplement 13 · unknownAP
2017-08-09Labeling · Supplement 6 · standardAP
2016-06-02Labeling · Supplement 4 · standardAP
2015-06-19Manufacturing (CMC) · Supplement 3 · unknownAP
2015-04-01Labeling · Supplement 2 · standardAP
2013-03-07Not Applicable · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →